ROCURONIUM BROMIDE INJECTION 10 MG — DIN 02469774
ROCURONIUM BROMIDE : 10 MG · JUNO PHARMACEUTICALS CORP. · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is ROCURONIUM BROMIDE INJECTION?
ROCURONIUM BROMIDE INJECTION 10 MG contains ROCURONIUM BROMIDE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02469774, held by JUNO PHARMACEUTICALS CORP., supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 05-May-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ROCURONIUM BROMIDE INJECTION used for?
Rocuronium Bromide Injection (rocuronium bromide) is indicated as an adjunct to general anesthesia to facilitate routine endotracheal intubation or rapid sequence (initiated at 60-90 seconds post-administration) intubation to provide skeletal muscle relaxation during surgery or mechanical ventilation. Rocuronium bromide is a non-depolarizing neuromuscular blocking agent with a rapid to intermediate onset and an intermediate duration of action depending on dose. Geriatrics (> 65 years of age): Lower maintenance doses and infusion rates are recommended as the duration of neuromuscular blockade tends to be longer in the elderly. Pediatrics (≤ 18 years of age): Rocuronium Bromide Injection is indicated for routine adjunct use in all pediatric patients, including term neonates and infants. Caution is advised in selecting the dosage for intubation and maintenance in neonates and infants because of limited controlled safety and efficacy data. Rocuronium Bromide Injection is not recommended for rapid sequence intubation in pediatric patients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Rocuronium Bromide cost around the world?
Rocuronium Bromide is listed on 6 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory); Romania publishes a max producer price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| South Africa | single exit price | 11 | 13 |
| Greece | producer price (ex-factory) | 5 | 5 |
| Saudi Arabia | public | 5 | 5 |
| United Arab Emirates | public | 4 | 4 |
| Bahrain | retail (max) | 2 | 2 |
| Romania | max producer price | 2 | 2 |
31 pack listings across 29 brand entries and 5 price bases, refreshed 03 Sep 2026. Ranges span every Rocuronium Bromide pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Rocuronium Bromide in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
10 holders have a Canadian DIN containing Rocuronium Bromide, across 12 DINs, of which 6 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SANDOZ CANADA INCORPORATED | 2 | 1 | ROCURONIUM BROMIDE INJECTION, ROCURONIUM BROMIDE INJECTION SDZ | Sourceable in Canada |
| AURO PHARMA INC | 1 | 1 | ROCURONIUM BROMIDE INJECTION | Sourceable in Canada |
| EUGIA PHARMA INC. | 1 | 1 | ROCURONIUM BROMIDE INJECTION | Sourceable in Canada |
| HIKMA CANADA LIMITED | 1 | 1 | ROCURONIUM BROMIDE INJECTION | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | ROCURONIUM BROMIDE INJECTION | Sourceable in Canada |
| JUNO PHARMACEUTICALS CORP. | 1 | 1 | ROCURONIUM BROMIDE INJECTION | Sourceable in Canada |
| OMEGA LABORATORIES LIMITED | 2 | 0 | INJECTABLE ROCURONIUM BROMIDE, ROCURONIUM BROMIDE INJECTION | No marketed DIN |
| MERCK CANADA INC | 1 | 0 | ZEMURON | No marketed DIN |
| PFIZER CANADA ULC | 1 | 0 | ROCURONIUM BROMIDE INJECTION | No marketed DIN |
| STERIMAX INC | 1 | 0 | ROCURONIUM BROMIDE INJECTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 10 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | VIALS 5 mL multiple dose vials containing 50 mg rocuronium bromide (10 mg/mL), supplied in 10 mL/20 mm USP type 1 glass vial, closed with 20 mm bromobutyl stopper and sealed with a 20 mm red cap printed with "Paralyzing Agent" in white, with a transparent polypropylene flip-off top cap, packed into a folding box. Available in boxes of 10. |
| Storage | Unopened vials: Rocuronium Bromide Injection should be stored under refrigeration (2°C - 8°C) until ready to use. To facilitate use in the operating room, the unopened vials may be stored up to 90 days at room temperature (15°C-30° C). Punctured vials: Punctured vials are stable for 30 days at 15°C – 30°C. Diluted solution: After dilution with infusion fluids in controlled and validated aseptic conditions, chemical and physical in-use stability has been demonstrated for 72 hours at 30°C. From a microbiological point of view, the diluted product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user/administrator and would normally not be longer than 24 hours at 2 to 8°C. If the diluted solution has taken place in controlled and validated aseptic conditions, it can be used up to 72 hours at 30°C. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Rocuronium Bromide |
|---|---|
| ATC code | M03AC09 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02469774 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2469774 |
| Brand name | ROCURONIUM BROMIDE INJECTION |
| Generic / active ingredient | ROCURONIUM BROMIDE : 10 MG |
| Market authorization holder | JUNO PHARMACEUTICALS CORP. |
| Health Canada schedule | Prescription |
| ATC code | M03AC09 |
| ATC anatomical main group | M — Musculo-skeletal system |
| ATC therapeutic subgroup | M03AC |
| Current status | MARKETED |
| Status date | 05-May-2026 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Rocuronium Bromide Injection should be administered only by intravenous route. This drug should be administered by or under the supervision of experienced clinicians familiar with the use of neuromuscular blocking agents. To avoid distress to the patient, Rocuronium Bromide Injection should not be administered before unconsciousness has been induced. It should not be mixed in the same syringe or administered simultaneously through the same needle with alkaline solutions (e.g., barbiturate solutions). Doses of Rocuronium Bromide Injection should be individualized in each patient. The method of anesthesia and the expected duration of surgery, the method of sedation and the expected duration of mechanical ventilation, the possible interaction with other drugs that are administered concomitantly, and the condition of the patient should be taken into account when determining the dose. A peripheral nerve stimulator should be used to measure neuromuscular function during administration of Rocuronium Bromide Injection in order to monitor drug effect, to determine the need for additional doses, and to confirm recovery from neuromuscular blockade. Inhalational anesthetics do potentiate the neuromuscular blocking effects of rocuronium bromide. This potentiation however, becomes clinically relevant in the course of anesthesia, when the volatile agents have reached the tissue concentrations required for this interaction. Consequently, the choice of an intubating dose of rocuronium bromide should not, therefore, be reduced below 0.45 mg/kg if routine tracheal intubation is to be performed or below 0.60 mg/kg if rapid intubation is to be performed. Yet adjustments with Rocuronium Bromide Injection should be made by administering smaller maintenance doses at less frequent intervals or by using lower infusion rates of Rocuronium Bromide Injection during long lasting procedures (longer than 1 hour) under inhalational anesthesia. Otherwise increases in the clinical duration (25-35%) and recovery time (20-70%) of neuromuscular blockade may be apparent in the presence of a halogenated inhalation agents. Continuous infusion or intermittent bolus dosing to support long term mechanical ventilation has not been studied sufficiently to support dosage recommendations.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container.
Warnings and precautions
Rocuronium Bromide Injection should be administered in carefully adjusted dosage by or under the supervision of experienced clinicians who are familiar with its actions and the possible complications of its use. The drug should not be administered unless personnel and facilities for resuscitation and life support (tracheal intubation, artificial ventilation, oxygen therapy), and an antagonist of Rocuronium Bromide Injection are immediately available. It is recommended that an adequate neuromuscular monitoring device be used to measure neuromuscular function during the administration of Rocuronium Bromide Injection in order to monitor drug effect, determine the need for additional doses, and confirm recovery from neuromuscular blockade. Rocuronium bromide has no known effect on consciousness, pain threshold, thinking, or memory. To avoid distress to the patient, neuromuscular blockade should not be induced before unconsciousness. Since rocuronium bromide causes paralysis of the respiratory muscles, ventilatory support is mandatory for patients treated with this drug until adequate spontaneous respiration is restored. As with all neuromuscular blocking agents, it is important to anticipate intubation difficulties, particularly when used as part of a Rapid Sequence Intubation technique. As with other neuromuscular blocking agents, residual neuromuscular blockade has been reported for rocuronium bromide. In order to prevent complications resulting from residual neuromuscular blockade, it is recommended to extubate only after the patient has recovered sufficiently from neuromuscular blockade. Geriatric patients (65 years or older) may be at increased risk for residual neuromuscular blockade. Other factors which could cause residual neuromuscular blockade after extubation in the post-operative phase (such as drug interactions or patient condition) should also be considered. The use of a reversal agent should be considered, especially in those cases where residual neuromuscular blockade is more likely to occur. Hypothermia reduces the requirement for the neuromuscular blocking agent. Administration of Rocuronium Bromide Injection results in paralysis, which may lead to respiratory arrest and death, a progression that may be more likely to occur in a patient for whom it is not intended. Confirm proper selection of intended product and avoid confusion with other injectable solutions that are present in critical care and other clinical settings. If another healthcare provider is administering the product, ensure that the intended dose is clearly labelled and communicated. The overall analysis of ECG data from two clinical pharmacology studies in pediatric patients indicates that the combined use of rocuronium with general anesthetic agents may prolong the QTc interval. Some of the prolongation may reach clinical significance. Routine ECG monitoring is recommended, especially in pediatric patients. The routine precautions for treating arrhythmia should be taken into consideration. Rocuronium bromide may be associated with increased pulmonary vascular resistance, so caution is appropriate in patients with pulmonary hypertension or valvular heart disease. Because rocuronium is excreted in urine and bile, it should be used with caution in patients with hepatic impairment. In these patient groups prolongation of action has been observed with doses of 0.6 mg/kg rocuronium bromide. Whenever the use of Rocuronium Bromide Injection, or any neuromuscular blocking agent, is contemplated in the ICU, it is recommended that a peripheral nerve stimulator be used continuously to monitor neuromuscular transmission during administration and recovery. In addition, patients should receive adequate analgesia and sedation. Furthermore, additional doses of Rocuronium Bromide Injection or any other neuromuscular blocking agent should not be given before there is a definite response to the first twitch. If no response is elicited, infusion administration should
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
6 of 12 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | AURO PHARMA INC | MARKETED | 02498820 |
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | 02517744 |
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | EUGIA PHARMA INC. | MARKETED | 02528657 |
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02318415 |
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | 02529831 |
| INJECTABLE ROCURONIUM BROMIDE | 10 MG | SOLUTION | OMEGA LABORATORIES LIMITED | CANCELLED PRE MARKET | 02539489 |
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | STERIMAX INC | APPROVED | 02442752 |
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | 02318121 |
| ROCURONIUM BROMIDE INJECTION | 10 MG | SOLUTION | OMEGA LABORATORIES LIMITED | CANCELLED POST MARKET | 02382415 |
| ROCURONIUM BROMIDE INJECTION SDZ | 10 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | 02390566 |
2 · Same class — other molecules in ATC M03AC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Rocuronium Bromide | INJECTABLE ROCURONIUM BROMIDE · ROCURONIUM BROMIDE INJECTION · ROCURONIUM BROMIDE INJECTION SDZ · ZEMURON | 12 | 6 | Yes |
| Cisatracurium | AJ-CISATRACURIUM · CISATRACURIUM BESYLATE INJECTION · CISATRACURIUM BESYLATE INJECTION (PRESERVATIVE-FREE) · CISATRACURIUM BESYLATE INJECTION MULTI-DOSE · +6 more | 13 | 1 | Yes |
| Pancuronium | PANCURONIUM BROMIDE - LIQ IV 1MG/ML · PANCURONIUM BROMIDE - LIQ IV 2MG/ML · PANCURONIUM BROMIDE 1MG/ML · PANCURONIUM BROMIDE 2MG/ML · +2 more | 6 | 0 | Not in Canada |
| Atracurium | ATRACURIUM - (FOR SINGLE DOSE ) · ATRACURIUM - (FOR MULTIPLE DOSE VIAL - WITH PRESERVATIVE) · ATRACURIUM BESYLATE INJECTION · TRACRIUM | 6 | 0 | Not in Canada |
| Vecuronium | NORCURON INJ 10MG/VIAL · VECURONIUM BROMIDE FOR INJECTION | 4 | 0 | Not in Canada |
| Mivacurium Chloride | MIVACRON | 1 | 0 | Not in Canada |
| Gallamine | FLAXEDIL INJ 20MG/ML | 1 | 0 | Not in Canada |
| Doxacurium Chloride | NUROMAX | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC M03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| M03AX | Botulinum Toxin | 16 | 12 |
| M03AB | Suxamethonium | 9 | 3 |
| M03AA | Dimethyltubocurarine · Tubocurarine | 3 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ROCURONIUM BROMIDE INJECTION called?
Also recorded in Canada as: rocuronium bromide 10 MG/ML Injectable Solution (US), 5 ML rocuronium bromide 10 MG/ML Injection (US), 10 ML rocuronium bromide 10 MG/ML Injection (US), ROCURONIUM BROMIDE (US), Zemuron (US), Esmeron (EU), Esmeron (UK), Rocunium (IN), Kabirocu (IN), Rocuronium Bromide (UK), Rocuronium Bromide (GLOBAL).
The same molecule, Rocuronium Bromide, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Esmeron | Latin | Bahrain, South Africa |
| Erunom | Latin | South Africa |
| Immaroc | Latin | South Africa |
| LAXIRA | Latin | Saudi Arabia |
| RocuLAX | Latin | Saudi Arabia |
| Rocuronium Bromide BOS | Latin | Saudi Arabia |
| Rocuronium Kabi | Latin | Saudi Arabia |
| RONIA | Latin | South Africa |
| RONMOR | Latin | Bahrain |
| Trakeze | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.